Andrzej Jakubowiak

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Andrzej J Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637 6613, USA
    Blood 120:1801-9. 2012
  2. doi request reprint Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Andrzej J Jakubowiak
    University of Michigan Cancer Center, Ann Arbor, MI, USA
    Br J Haematol 158:472-80. 2012
  3. doi request reprint Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    Andrzej J Jakubowiak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:1960-5. 2012
  4. doi request reprint Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives
    Andrzej Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637, USA
    Semin Hematol 49:S16-32. 2012

Detail Information

Publications4

  1. doi request reprint A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Andrzej J Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637 6613, USA
    Blood 120:1801-9. 2012
    ..CRd was well tolerated with exceptional response rates. This study is registered at http://www.clinicaltrials.gov as NCT01029054...
  2. doi request reprint Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Andrzej J Jakubowiak
    University of Michigan Cancer Center, Ann Arbor, MI, USA
    Br J Haematol 158:472-80. 2012
    ..Response was associated with phospho-Akt in pharmacodynamic studies. Perifosine-lenalidomide-dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM...
  3. doi request reprint Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    Andrzej J Jakubowiak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:1960-5. 2012
    ..To evaluate the maximum-tolerated dose (MTD), safety, and efficacy of elotuzumab in combination with bortezomib in patients with relapsed or relapsed and refractory multiple myeloma (MM)...
  4. doi request reprint Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives
    Andrzej Jakubowiak
    University of Chicago Medical Center, Chicago, IL 60637, USA
    Semin Hematol 49:S16-32. 2012
    ....